Please use this identifier to cite or link to this item:
Title: Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release
Author: Roca Cusachs, Alex
Aracil vilar, Joaquín
Calvo Gómez, Carlos
Vaquer Pérez, José Vicente
Laporta Crespo, Félix
Rojas Serrano, María José
Guglietta, Antonio
Gropper, Savion
Sobrino, Javier
Keywords: Medicaments d'alliberament retardat
Pressió sanguínia
Delayed-action drugs
Blood pressure
Issue Date: 2008
Publisher: Wiley Hindawi Publishing
Abstract: The efficacy of a new torasemide prolonged release (PR) formulation to torasemide immediate release (IR) was compared in a randomized noninferiority double‐blind trial. Patients with newly diagnosed mild‐to‐moderate hypertension or unresponsive or poor tolerability to previous antihypertensive monotherapy received 5 mg/day of torasemide‐PR (n = 219) or torasemide‐IR (n = 223) for 12 weeks (uptitration to 10 mg/day if no response at 4 or 8 weeks). Mean diastolic blood pressure (DBP) reduction in the torasemide‐PR group (11.6 ± 7.1 mmHg, 95% confidence interval [CI] 10.6-12.5) versus torasemide‐IR (11.3 ± 7.5 mmHg, 95% CI 10.2-12.3) met the noninferiority criterion of a nonsided 97.5% CI lower than the preestablished margin of 2 mmHg. A significantly higher percentage of patients in the torasemide‐PR group achieved adequate BP control after 8 and 12 weeks. Ambulatory 24‐h BP monitoring (ABPM) measurements in a subset of 100 patients showed greater daytime SBP reductions in the torasemide‐PR group (128.4 ± 9.9 mmHg vs. 133.5 ± 10.4 mmHg, P < 0.05). Safety and tolerability of both formulations were similar.
Note: Reproducció del document publicat a:
It is part of: Cardiovascular Therapeutics, 2008, vol. 26, num. 2, p. 91-100
Related resource:
ISSN: 1755-5914
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
602170.pdf281.22 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons